Bexion Pharmaceuticals
Manufacturing · Kentucky, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
632 Russell St, Covington, Kentucky, 410...Phone Number
(859) 446-7386Website
www.bexionpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative biologic therapies for treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). Their lead product, BXQ-350, targets metastatic colorectal cancer while aiming to alleviate neuropathic pain associated with current treatments. The company has shown promising Phase 1 data and is committed to expanding its portfolio to address additional cancer types and broader neuropathic pain treatments. With a multidisciplinary team, Bexion is dedicated to creating patient-centered therapeutics that improve the lives of cancer patients.Explore more
Bexion Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bexion Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Bexion Pharmaceuticals has new funding data
Bexion Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Bexion Pharmaceuticals
Click to see if Bexion Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Bexion Pharmaceuticals launches new products
Check out if Bexion Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Bexion Pharmaceuticals recently announced quarterly report
Check if Bexion Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Bexion Pharmaceuticals
Find more new buyers
Compare Similar Companies to Bexion Pharmaceuticals
Compare insights from companies similar to Bexion Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bexion Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bexion Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bexion Pharmaceuticals.
Bexion Pharmaceuticals financials insights
Gather financial insights about Bexion Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Debt
$313K
Bexion Pharmaceuticals Tech Stack
A closer look at the technologies used by Bexion Pharmaceuticals
See more technologies
Most Recent Scoops
Person-Based
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Person-Based
Person-Based
New Hire
Executive Move
Bexion Pharmaceuticals News & Media
Bexion Pharmaceuticals, Inc. Announces Acceptance of Abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
COVINGTON, Ky., May 28, 2025 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that two abstracts were...Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
COVINGTON, Ky., April 25, 2025 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that the Company will...Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025
COVINGTON, Ky., Jan. 8, 2025 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel, first-in-class biologic therapy to treat solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), today announced a poster presentation at...Charles R. Scheper, Chairman of Bexion Pharmaceuticals Board, Named Great Living Cincinnatian
COVINGTON, Ky., Dec. 6, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that its Chairman of the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bexion Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative biologic therapies for treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). Their lead product, BXQ-350, targets metastatic colorectal cancer while aiming to alleviate neuropathic pain associated with current treatments. The... Read More
